Your browser doesn't support javascript.
loading
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
Becnel, Melody R; Nastoupil, Loretta J; Samaniego, Felipe; Davis, Richard E; You, M J; Green, Michael; Hagemeister, Fredrick B; Fanale, Michelle A; Fayad, Luis E; Westin, Jason R; Wang, Michael; Oki, Yasuhiro; Forbes, Sheryl G; Feng, Lei; Neelapu, Sattva S; Fowler, Nathan H.
Afiliação
  • Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davis RE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • You MJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Green M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fanale MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fayad LE; Seattle Genetics Inc., Bothell, WA, USA.
  • Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oki Y; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Forbes SG; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fowler NH; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Br J Haematol ; 185(5): 874-882, 2019 06.
Article em En | MEDLINE | ID: mdl-30919940
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Zona Marginal Tipo Células B / Inibidores da Angiogênese / Rituximab / Lenalidomida Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Zona Marginal Tipo Células B / Inibidores da Angiogênese / Rituximab / Lenalidomida Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos